19 5月 2019 by admin in UncategorizedComments Crescendo awarded with EU patent on immunoglobulin libraries from transgenic animals
16 5月 2019 by admin in UncategorizedComments TEMPEST THERAPEUTICS STARTS PHASE I/IB CLINICAL TRIAL WITH FIRST-IN-CLASS PPAR ALPHA ANTAGONIST
15 5月 2019 by admin in UncategorizedComments resTORbio Reports First Quarter 2019 Financial Results and Corporate Update
08 5月 2019 by admin in UncategorizedComments NextCure Announces Pricing of Initial Public Offering of Common Stock
01 5月 2019 by admin in UncategorizedComments Syros Reports First Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
02 4月 2019 by admin in UncategorizedComments Theodora Harold to be appointed new CEO at Crescendo Biologics
15 3月 2019 by admin in UncategorizedComments Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019
07 3月 2019 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs
04 3月 2019 by admin in UncategorizedComments NextCure and Yale Publish Nature Medicine Paper Detailing Novel Immunomedicine Target Siglec-15
28 2月 2019 by admin in UncategorizedComments Syros to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 7, 2019
12 2月 2019 by admin in UncategorizedComments NextCure Announces Formation of Scientific Advisory Board to Guide Development of its Portfolio of Immunomedicines
06 1月 2019 by admin in UncategorizedComments Syros Announces Strategic Priorities and Expected Milestones
03 1月 2019 by admin in UncategorizedComments Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda
05 12月 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
13 11月 2018 by admin in UncategorizedComments Tempest Data Provide POC for PPAR Alpha’s Role in Cancer
06 11月 2018 by admin in UncategorizedComments resTORbio Appoints Michael Grissinger to its Board of Directors
06 11月 2018 by admin in UncategorizedComments Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018
05 11月 2018 by admin in UncategorizedComments Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®
16 10月 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces Two CNTX-4975 Presentations at the 2018 American College of Rheumatology Annual Meeting
08 10月 2018 by admin in UncategorizedComments Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic
02 10月 2018 by admin in UncategorizedComments Crescendo Biologics shortlisted for Private Financing Deal of the Year at 2018 Scrip Awards
24 9月 2018 by admin in UncategorizedComments Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer
24 9月 2018 by admin in UncategorizedComments Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer
20 9月 2018 by admin in UncategorizedComments Crescendo Biologics shortlisted for Lifestars Awards 2018
19 9月 2018 by admin in UncategorizedComments Crescendo Biologics shortlisted for Cambridge Independent Science and Technology Awards 2018
18 9月 2018 by admin in UncategorizedComments resTORbio Appoints Meredith Manning as Chief Commercial Officer
11 9月 2018 by admin in UncategorizedComments Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer
06 9月 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces CNTX-4975 Data Presentation at PAINWeek 2018 National Conference
04 9月 2018 by admin in UncategorizedComments TEMPEST THERAPEUTICS NAMES DR. GINNA LAPORT CMO – Dr. Alicia Levey promoted to CBO –
15 8月 2018 by admin in UncategorizedComments Centrexion Therapeutics Appoints Dan Mendelson to its Board of Directors
15 8月 2018 by admin in UncategorizedComments resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors
14 8月 2018 by admin in UncategorizedComments Crescendo Biologics Reaches Technical Milestone for a Second Target in Strategic Collaboration with Takeda
07 8月 2018 by admin in UncategorizedComments Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
31 7月 2018 by admin in UncategorizedComments Syros to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
30 7月 2018 by admin in UncategorizedComments Centrexion Therapeutics Appoints Financial Executive Nick Harvey as Chief Financial Officer
25 7月 2018 by admin in UncategorizedComments resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101
